NCT06601621 Study on the Impact of Electroacupuncture Combined With Self-Acupressure on the Quality of Life of Patients With Early-Stage Breast Cancer Undergoing Chemotherapy
| NCT ID | NCT06601621 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jiuda Zhao |
| Condition | Electroacupuncture |
| Study Type | INTERVENTIONAL |
| Enrollment | 192 participants |
| Start Date | 2024-10-19 |
| Primary Completion | 2026-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 192 participants in total. It began in 2024-10-19 with a primary completion date of 2026-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized controlled clinical trial aims to evaluate the effect of electroacupuncture combined with self-acupressure on the quality of life of early-stage breast cancer patients receiving chemotherapy.
Eligibility Criteria
Inclusion Criteria: 1. Aged 18 years or older and aged 75 years or younger, inclusive. with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; 2. Patients who have not received prior chemotherapy and are scheduled to receive at least 4 cycles of adjuvant or neoadjuvant chemotherapy or combination targeted therapy; 3. Normal organ function with platelets ≥ 100\*10\^9/ L, hemoglobin ≥ 90 g/L, serum creatinine ≤ 1.5 mg/dl (133 mmol/L), or creatinine clearance ≥ 60 ml/min, total bilirubin ≤ 1.5 times the upper limit of normal (ULN), alanine aminotransferase ≤ 2.5 times ULN, and aspartate aminotransferase ≤ 2.5 times ULN; 4. Premenopausal women need appropriate contraception; 5. Ability to understand the study well and complete the study questionnaire. Exclusion Criteria: 1. Patients with needle phobia or allergy to stainless steel needles; and 2. Current diagnosis of mental illness (e.g., major depression, obsessive-compulsive disorder, or schizophrenia); 3. History of autoimmune diseases, blood disorders, or organ transplantation, or long-term use of hormones or immunosuppressants; 4. Comorbid bleeding disorders or thyroid dysfunction; 5. Implantation of a pacemaker; pregnancy or breastfeeding; 6. A plan for adjuvant radiotherapy in the upcoming chemotherapy cycle; 7. Current active infection; 8. Acupuncture treatment within the last four weeks; 9. Patients who are allergic to the drugs used; 10. Use of other Traditional Chinese Medicine (TCM) techniques such as Chinese herbs in the next chemotherapy cycle.
Frequently Asked Questions
Who can join the NCT06601621 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Electroacupuncture. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06601621 currently recruiting?
Yes, NCT06601621 is actively recruiting participants. Visit ClinicalTrials.gov or contact Jiuda Zhao to inquire about joining.
Where is the NCT06601621 trial being conducted?
This trial is being conducted at Xining, China.
Who is sponsoring the NCT06601621 clinical trial?
NCT06601621 is sponsored by Jiuda Zhao. The trial plans to enroll 192 participants.